All In Biotech

Drug Trial Radar · NCT05714839

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 123 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

123

Planned (sponsor's estimate)

Start

Jun 14, 2023

Primary completion

Aug 3, 2028

Study completion Aug 3, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study consists of three parts: * Part 1: The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent belantamab in participants with refractory multiple myeloma (RRMM) who have received at least 3 prior therapies (4L+). * Part 2: The primary purpose of this part is to evaluate the safety, tolerability, and clinical activity of different doses of belantamab in combination with a fixed dose of Belantamab mafodotin (delivered as separate drugs) in participants with RRMM who have received at least 3 prior therapies (4L+). * Part 3: The Primary purpose of this part will evaluate the clinical activity of a selected dose of the belantamab in combination with the pomalidomide-dexamethasone (Pd) standard of care (SoC) backbone. The study will focus on participants with multiple myeloma who have undergone at least one prior line of therapy, including treatment with lenalidomide.

Conditions

  • Multiple Myeloma

Interventions

  • BelantamabDrug

    Belantamab will be administered.

  • Belantamab mafodotinDrug

    Belantamab mafodotin will be administered.

  • PomalidomideDrug

    Pomalidomide will be administered.

  • DexamethasoneDrug

    Dexamethasone will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts 1, 2 and 3: Number of Participants with any Adverse EventTime frame: Up to 52 months
  2. Part 1 (Dose escalation cohort) and Part 2: Number of Participants with Dose Limiting Toxicities (DLTs)Time frame: Cycle 1 (Each cycle is of 28 days)
  3. Part 1, 2 and 3: Number of Participants with Worst Case Grade Change from Baseline in Laboratory and Vital Sign ParametersTime frame: Up to 52 months
  4. Part 2: Number of Participants with severity of ocular events by the Keratopathy Visual Acuity (KVA) scaleTime frame: Up to 52 months
  5. Part 2: Overall Response Rate (ORR)Time frame: Up to 52 months
  6. Part 3: Very Good Partial Response and better rate (VGPR+)Time frame: Up to 52 months

Locations

59 sites in 15 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Bullhead City, Arizona · Recruiting

  • GSK Investigational Site

    Los Angeles, California · Recruiting

  • GSK Investigational Site

    Pembroke Pines, Florida · Recruiting

  • GSK Investigational Site

    Boston, Massachusetts · Recruiting

  • GSK Investigational Site

    Grand Rapids, Michigan · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    Chapel Hill, North Carolina · Recruiting

  • GSK Investigational Site

    Wilson, North Carolina · Recruiting

  • GSK Investigational Site

    Canton, Ohio · Recruiting

  • GSK Investigational Site

    Chattanooga, Tennessee · Recruiting

  • GSK Investigational Site

    Nashville, Tennessee · Recruiting

  • GSK Investigational Site

    Fort Worth, Texas · Recruiting

  • GSK Investigational Site

    Capital Federal, Argentina · Recruiting

  • GSK Investigational Site

    Ciudadela, Argentina · Completed

  • GSK Investigational Site

    Rosario, Argentina · Recruiting

  • GSK Investigational Site

    San Juan Bautista, Argentina · Recruiting

  • GSK Investigational Site

    Viedma, Argentina · Recruiting

  • GSK Investigational Site

    Monte Grande, Buenos Aires, Argentina · Recruiting

  • GSK Investigational Site

    Fitzroy, Victoria, Australia · Recruiting

  • GSK Investigational Site

    Nedlands, Western Australia, Australia · Completed

  • GSK Investigational Site

    Joinville, Brazil · Recruiting

  • GSK Investigational Site

    Salvador, Brazil · Recruiting

  • GSK Investigational Site

    São Paulo, Brazil · Recruiting

  • GSK Investigational Site

    Guangzhou, China · Recruiting

  • GSK Investigational Site

    Suzhou, China · Recruiting

  • GSK Investigational Site

    Helsinki, Finland · Recruiting

  • GSK Investigational Site

    Kuopio, Finland · Recruiting

  • GSK Investigational Site

    Tampere, Finland · Recruiting

  • GSK Investigational Site

    Turku, Finland · Recruiting

  • GSK Investigational Site

    Dresden, Germany · Recruiting

  • GSK Investigational Site

    Beersheba, Israel · Recruiting

  • GSK Investigational Site

    Haifa, Israel · Recruiting

  • GSK Investigational Site

    Jerusalem, Israel · Recruiting

  • GSK Investigational Site

    Petah Tikva, Israel · Recruiting

  • GSK Investigational Site

    Ramat Gan, Israel · Recruiting

  • GSK Investigational Site

    Tel Aviv, Israel · Recruiting

  • GSK Investigational Site

    Aomori, Japan · Recruiting

  • GSK Investigational Site

    Chiba, Japan · Recruiting

  • GSK Investigational Site

    Ehime, Japan · Recruiting

  • GSK Investigational Site

    Kanagawa, Japan · Recruiting

Showing 40 of 59 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.